Journal: Theranostics

Article Title: A hydrogen peroxide economizer for on-demand oxygen production-assisted robust sonodynamic immunotherapy

doi: 10.7150/thno.64862

Figure Lengend Snippet: MFC characterization. (A) Schematic illustration of the synthetic procedures for engineered MFCs. (B-D) TEM and SEM images of Fe-PDAP. (E-G) TEM and SEM images of MFC. (H) Size distribution of Fe-PDAP, FC, and MFC. (I) Zeta potentials of Fe-PDAP, FC, and MFC. (J) UV/vis absorption spectra of Fe-PDAP, Ce6, FC, and MFC. (K) XRD patterns of MFC and Fe-PDAP. (L) XPS high-resolution Fe2p spectrum of MFC. (M) Elemental mappings of MFC.

Article Snippet: Ce6 was obtained from J&K Chemical Co. aPD-1 was provided by BioxCell (clone: RMP1-14, catalog no. BE0146).

Techniques:

Journal: Theranostics

Article Title: A hydrogen peroxide economizer for on-demand oxygen production-assisted robust sonodynamic immunotherapy

doi: 10.7150/thno.64862

Figure Lengend Snippet: In vitro on demand catalase-like activity of the NPs and the H 2 O 2 content during treatment. (A) Ce6 controlled release of MFC triggered by US irradiation. (B) TEM of MFC after US exposure. (C) Schematic illustration of the therapeutic mechanism in the presence of US-detachable catalase-like nanozymes. (D) The production of O 2 by different NPs with or without US irradiation. (E) Extracellular H 2 O 2 content after different treatments measured by Amplex Red. (F) Intracellular H 2 O 2 content after different treatments measured by Amplex Red. (G) Confocal laser scanning microscopy (CLSM) images of RDPP in 4T1 cells after different treatments. Scale bar: 100 μm.

Article Snippet: Ce6 was obtained from J&K Chemical Co. aPD-1 was provided by BioxCell (clone: RMP1-14, catalog no. BE0146).

Techniques: In Vitro, Activity Assay, Irradiation, Confocal Laser Scanning Microscopy

Journal: Theranostics

Article Title: A hydrogen peroxide economizer for on-demand oxygen production-assisted robust sonodynamic immunotherapy

doi: 10.7150/thno.64862

Figure Lengend Snippet: In vitro cytotoxicity assay and therapeutic effects. (A) ESR spectra of MFC with or without US irradiation. (B) Quantitative analysis of ROS production by MFC with or without US irradiation using SOSG as a probe. (C) Cell viability of 4T1 cells after incubation with MFC for 24 h. (D) Cell viability of 4T1 cells after treatment with Ce6 or MFC at various concentrations of Ce6 after exposure to US irradiation. (E) CLSM images of 4T1 cells and SKOV3 cells stained with DCFH-DA after different treatments among different groups. Scale bar: 100 μm. (F) CLSM images of 4T1 cells costained with PI and calcein-AM after different treatments. Scale bar: 100 μm. (G) Representative CLSM images showing CRT exposure on 4T1 tumor cells after different treatments. scale bar = 25 μm.

Article Snippet: Ce6 was obtained from J&K Chemical Co. aPD-1 was provided by BioxCell (clone: RMP1-14, catalog no. BE0146).

Techniques: In Vitro, Cytotoxicity Assay, Irradiation, Incubation, Staining

Journal: Theranostics

Article Title: A hydrogen peroxide economizer for on-demand oxygen production-assisted robust sonodynamic immunotherapy

doi: 10.7150/thno.64862

Figure Lengend Snippet: In vitro active targeting effects of MFC. (A) SDS-PAGE analysis of MFC, cancer cell membranes, and FC. (B-C) CLSM images of the 4T1 cells incubated with FC and MFC, and the corresponding quantitative fluorescence intensity of Ce6. Scale bar: 100 μm. (D-E) CLSM images of 4T1 cells treated with FC cloaked with different cancer cell membranes and the corresponding quantitative fluorescence intensity of Ce6. Scale bar: 100 μm. (F) Intracellular Fe content in 4T1 cells after treatment with FC cloaked with different cancer cell membranes. (G-H) CLSM images of 4T1 cells stained with DCFH-DA after treatment with FC cloaked with different cancer cell membranes and the corresponding fluorescence intensity of DCF. Scale bar: 100 μm.

Article Snippet: Ce6 was obtained from J&K Chemical Co. aPD-1 was provided by BioxCell (clone: RMP1-14, catalog no. BE0146).

Techniques: In Vitro, SDS Page, Incubation, Fluorescence, Staining

Journal: Journal of Nanobiotechnology

Article Title: Hemin-incorporating DNA nanozyme enabling catalytic oxygenation and GSH depletion for enhanced photodynamic therapy and synergistic tumor ferroptosis

doi: 10.1186/s12951-022-01617-0

Figure Lengend Snippet: Schematical showing the preparation of DF with AS1411 G4 motif for Ce6 loading and hemin incorporation for tumor targeting PDT/ferroptosis combinatorial therapy

Article Snippet: Hemin and Chlorin e6 (Ce6) were purchased from Frontier Scientific Co., Ltd (Utah, USA).

Techniques:

Journal: Journal of Nanobiotechnology

Article Title: Hemin-incorporating DNA nanozyme enabling catalytic oxygenation and GSH depletion for enhanced photodynamic therapy and synergistic tumor ferroptosis

doi: 10.1186/s12951-022-01617-0

Figure Lengend Snippet: A Schematic showing the design of template sequence and the preparation of DF. B The TEM micro-images of DF and CH/DF. C The SEM micro-image of CH/DF. D DLS and E surface charge measurements of DF and CH/DF. Inset: the appearance of the nanoparticles after centrifugation. F The fluorescence spectra of Ce6 before and after loading into DF. G The elemental mapping micro-image of CH/DF

Article Snippet: Hemin and Chlorin e6 (Ce6) were purchased from Frontier Scientific Co., Ltd (Utah, USA).

Techniques: Sequencing, Centrifugation, Fluorescence

Journal: Journal of Nanobiotechnology

Article Title: Hemin-incorporating DNA nanozyme enabling catalytic oxygenation and GSH depletion for enhanced photodynamic therapy and synergistic tumor ferroptosis

doi: 10.1186/s12951-022-01617-0

Figure Lengend Snippet: A Ex vivo imaging the biodistribution of CH/DF and free Ce6 at 12 h post-injection into tumor bearing mice. B The intensity quantification at different organs based on the fluorescence images in A . C Dynamic monitoring the tumor growth after various treatments. D The appearance and E weight of the tumors at day 16 post various treatments. F Tumor H&E staining images, fluorescent staining of TUNEL and caspase-3 of the mice with different treatments

Article Snippet: Hemin and Chlorin e6 (Ce6) were purchased from Frontier Scientific Co., Ltd (Utah, USA).

Techniques: Ex Vivo, Imaging, Injection, Fluorescence, Staining, TUNEL Assay

Journal: Journal of Pharmaceutical Analysis

Article Title: Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis

doi: 10.1016/j.jpha.2023.11.011

Figure Lengend Snippet: Cellular uptake and penetration performance of hyaluronan-Lip@Prussian blue nanoparticles (HA-Lip@PB NPs) in vitro . (A, B) Fluorescence images of cellular uptake (A) and fluorescence intensity analysis (B) of Lip@PB NPs labeling with fluorophore Ce6 (Lip@PB Ce6 NPs) and HA-Lip@PB NPs labeling with fluorophore Ce6 (HA-Lip@PB Ce6 NPs) in BGC-823 cells at 2, 4, and 6 h. (C, D) Fluorescence images by confocal laser scanning microscope (CLSM) (C) and fluorescence intensity analysis (D) of BGC-823 cells incubated with free Ce6, Lip@PB Ce6 , HA-Lip@PB Ce6 and HA + HA-Lip@PB Ce6 NPs for 4 h. (E) Fluorescence images of multicellular spheroids, after incubation with free Ce6, and HA-Lip@PB Ce6 NPs for 24 h. (F) Mean intensity along the solid white lines in the Z-axis plotted of BGC-823 multicellular spheroids (MCSs). Bars represented means ± standard deviation (SD) ( n = 3). ∗∗∗ P < 0.001, ns: not significant, FI: fluorescence intensity.

Article Snippet: Chlorine6 (Ce6) was purchased from Shanghai Yuanye Bio-Technology Co., Ltd (Shanghai, China).

Techniques: In Vitro, Fluorescence, Labeling, Laser-Scanning Microscopy, Incubation, Standard Deviation

Journal: Journal of Pharmaceutical Analysis

Article Title: Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis

doi: 10.1016/j.jpha.2023.11.011

Figure Lengend Snippet: Biodistribution, intratumor penetration and pharmacokinetic of hyaluronan-Lip@Prussian blue nanoparticles labeling with fluorophore Ce6 (HA-Lip@PB Ce6 NPs) in vivo . (A, B) Biodistribution of HA-Lip@PB Ce6 NPs and Lip@PB ce6 NPs in BGC-823 tumor-bearing mice over time measured by the fluorescence (A) and quantitative (B) analysis. (C, D) Fluorescence distribution (C) and quantitative fluorescence analysis (D) of major organs after 12, 24, 48 h post-injection. (E, F) Intratumor penetration ability of Lip@PB Ce6 NPs (E) and HA-Lip@PB ce6 NPs (F) in frozen tumor sections. Quantitative fluorescence analysis of tumors: the Ce6 fluorescence (red) intensity along the yellow line from tumor surface to tumor core was analyzed by Image J software. (G) Blood fluorescence intensity (FI) of Ce6, HA-Lip@PB Ce6 NPs over time. (H) Pharmacokinetic curves of Ce6 and HA-Lip@PB Ce6 NPs after different time points. Mean ± standard deviation (SD) ( n = 3). ∗ P < 0.05.

Article Snippet: Chlorine6 (Ce6) was purchased from Shanghai Yuanye Bio-Technology Co., Ltd (Shanghai, China).

Techniques: Labeling, In Vivo, Fluorescence, Injection, Software, Standard Deviation

Journal: ACS nano

Article Title: Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy

doi: 10.1021/acsnano.6b07525

Figure Lengend Snippet: A scheme illustrating the chemical composition of AQ4N-hCe6-liposome, which can serve as a multifunctional theranostic agent for multimodal imaging and PDT-induced, hypoxia-activated cancer therapy.

Article Snippet: For PET imaging, 4T1 tumor-bearing mice (3 mice per group) received i.v. injection of the 64 Cu-labeled AQ4N- h Ce6-liposome at a dose of ~10 MBq and were imaged using a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc.) at different time intervals.

Techniques: Imaging

Journal: ACS nano

Article Title: Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy

doi: 10.1021/acsnano.6b07525

Figure Lengend Snippet: Characterization of AQ4N-hCe6-liposome. (a) DLS size distributions of AQ4N-hCe6-liposome and plain hCe6-liposome. (b) A TEM image of AQ4N-hCe6-liposome. (c) UV–vis-NIR absorbance spectra of AQ4N-hCe6-liposome, plain hCe6-liposome, and free AQ4N. (d) Singlet oxygen generation abilities of AQ4N-hCe6-liposome and plain hCe6-liposome determined by using SOSG, whose recovered fluorescence indicated the generation of single oxygen. The concentration of hCe6 was 5 μM in these experiments. The error bars were based on triplicate measurements.

Article Snippet: For PET imaging, 4T1 tumor-bearing mice (3 mice per group) received i.v. injection of the 64 Cu-labeled AQ4N- h Ce6-liposome at a dose of ~10 MBq and were imaged using a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc.) at different time intervals.

Techniques: Fluorescence, Concentration Assay

Journal: ACS nano

Article Title: Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy

doi: 10.1021/acsnano.6b07525

Figure Lengend Snippet: Intracellular internalization and cytotoxicity of AQ4N-hCe6-liposome. (a) CLSM observation of intracellular internalization profiles of AQ4N-hCe6-liposome, plain hCe6-liposome, and free AQ4N after incubation with 4T1 cells. DAPI, Ce6, and AQ4N were excited at 404, 488, and 633 nm, respectively. (b) Cytotoxicity of AQ4N-hCe6-liposome to 4T1 cells under normoxia and hypoxia conditions measured by the standard MTT assay. The error bars were based on triplicate measurements. (c) Cytotoxicity of AQ4N-hCe6-liposome to 4T1 cells in the presence or absence of 660 nm LED light irradiation recorded by the standard MTT assay. The error bars were based on triplicate measurements.

Article Snippet: For PET imaging, 4T1 tumor-bearing mice (3 mice per group) received i.v. injection of the 64 Cu-labeled AQ4N- h Ce6-liposome at a dose of ~10 MBq and were imaged using a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc.) at different time intervals.

Techniques: Incubation, MTT Assay, Irradiation

Journal: ACS nano

Article Title: Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy

doi: 10.1021/acsnano.6b07525

Figure Lengend Snippet: In vivo multimodal imaging and pharmacokinetic behaviors of AQ4N-hCe6-liposome. (a) PET images of 4T1 tumor-bearing mice with i.v. injection of 64Cu2+-labeled AQ4N-hCe6-liposome recorded at different time intervals p.i. The tumors are indicated with yellow arrows. (b) Quantification of AQ4N-64Cu-hCe6-liposome levels in the liver, heart, tumor, and muscle of 4T1 tumor bearing mice at various time points p.i. (c) Biodistribution of AQ4N-64Cu-hCe6-liposome in various organs and tissues of 4T1 tumor-bearing mice at 24 h p.i. as determined by 64Cu radioactivity measurement by a gamma counter. Error bars were based on the standard errors of the mean of triplicate samples. (d) PA imaging of tumor regions recorded before and 24 h post-i.v. injection of AQ4N-hCe6-liposome. (e) Fluorescence imaging of 4T1 tumor bearing mice with i.v. injection of AQ4N-hCe6-liposome at 1 and 24 h p.i. The tumors are indicated with black dashed circles. (f and g) Semiquantitatively analyzing the PA (f) and fluorescence (FL) signal (g) of AQ4N-hCe6-liposome in tumors based on the images shown in (d and e). Error bars were based on triplicate measurements.

Article Snippet: For PET imaging, 4T1 tumor-bearing mice (3 mice per group) received i.v. injection of the 64 Cu-labeled AQ4N- h Ce6-liposome at a dose of ~10 MBq and were imaged using a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc.) at different time intervals.

Techniques: In Vivo, Imaging, Injection, Labeling, Radioactivity, Fluorescence

Journal: ACS nano

Article Title: Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy

doi: 10.1021/acsnano.6b07525

Figure Lengend Snippet: Tumor hypoxia and blood vasculature evolutions induced by photodynamic treatment with AQ4N-hCe6-liposome. (a) Ex vivo immunofluorescence staining of tumor slices collected from AQ4N-hCe6-liposome injected mice with different treatments. (b) Semiquantitative analysis of the percentages of positive hypoxia regions before and after 660 nm LED light irradiation based on the images shown in (a). I, II, III, and IV stand for those tumors collected before and at 5 min, 4 h, and 24 h post-irradiation with 660 nm LED light (2 mW cm−2, 1 h), respectively. (c) Ex vivo immunofluorescence staining showing the changes of blood vessels (green) in tumors collected from the 4T1-tumor bearing mice with i.v. injection of AQ4N-hCe6-liposome before and at 4 h post-660 nm LED light irradiation (2 mW cm−2, 1 h). (d) Semiquantitative analysis of the effective blood vessel areas, which appears as opened circles indicated with white arrows, in the slices shown in (c) using the Image-Pro Plus 6.0. software.

Article Snippet: For PET imaging, 4T1 tumor-bearing mice (3 mice per group) received i.v. injection of the 64 Cu-labeled AQ4N- h Ce6-liposome at a dose of ~10 MBq and were imaged using a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc.) at different time intervals.

Techniques: Ex Vivo, Immunofluorescence, Staining, Injection, Irradiation, Software

Journal: ACS nano

Article Title: Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy

doi: 10.1021/acsnano.6b07525

Figure Lengend Snippet: In vivo cancer combination therapy with sequentially activated AQ4N-hCe6-liposome. (a) Tumor growth curves of mice after various different treatments as indicated. V and Vo stand for the tumor volumes after and before the treatment, respectively. Error bars were based on five mice in each group. (b) Average tumor weights from different groups collected at 14 d after the treatment. (c and d) H&E (c) and TUNEL staining (d) of tumor slices collected from mice from various groups at 24 h post-660 nm LED light irradiation. Groups I, II, III, IV, and V stand for saline treatment (control), hCe6-liposome + L660 nm, hCe6-liposome + free AQ4N + L660 nm, AQ4N-hCe6-liposome only, −and AQ4N-hCe6-liposome + L660 nm in (d–f), respectively. L660 nm stands for 1 h irradiation with 660 nm LED light (2 mW cm2).

Article Snippet: For PET imaging, 4T1 tumor-bearing mice (3 mice per group) received i.v. injection of the 64 Cu-labeled AQ4N- h Ce6-liposome at a dose of ~10 MBq and were imaged using a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc.) at different time intervals.

Techniques: In Vivo, TUNEL Assay, Staining, Irradiation